Personalized tamoxifen: A step closer but miles to go

Aditya Bardia, Vered Stearns

Research output: Contribution to journalComment/debatepeer-review

5 Scopus citations


Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals. Clin Cancer Res; 16(17); 4308-10.

Original languageEnglish (US)
Pages (from-to)4308-4310
Number of pages3
JournalClinical Cancer Research
Issue number17
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Personalized tamoxifen: A step closer but miles to go'. Together they form a unique fingerprint.

Cite this